Theravance (NASDAQ: THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELVARTM or BREOTM ELLIPTATM (FF/VI), ANOROTM ELLIPTATM (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need.
View all » Recent Releases
View all »Presentations & Events
Jun 5, 2013 at 10:30 AM ET
Jefferies 2013 Global Healthcare Conference
Jun 13, 2013 at 8:40 AM PT
Goldman Sachs 34th Annual Global Healthcare Conference